TransMedics Group Inc. (TMDX)
Down 52%, Is TransMedics Stock a Buy on the Dip?
Sales growth is tapering off for this provider of delivery services for transplant organs.
ATTENTION TransMedics Group, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
Why TransMedics Stock Plunged in October
The organ transplant specialist posted disappointing results in its third-quarter report.
Levi & Korsinsky Announces an Investigation on Behalf of TransMedics Group, Inc. (TMDX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
TMDX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your TransMedics Group, Inc. investment
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
TransMedics Group, Inc. Being Investigated on Behalf of TransMedics Group, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by TransMedics Group, Inc. (TMDX)
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
1 Top Growth Stock Down 50% to Buy After Its Recent Pullback
TransMedics quickly became the leader in liver, heart, and lung transplants, but its third-quarter earnings left the market worried. Here's why I believe its pullback in share price is an opportunity.
TransMedics Group, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - TMDX
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
TransMedics Group, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - TMDX
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TransMedics: Maintaining A Neutral Stance After A Difficult Q3
TMDX which was outperforming the S&P500 by 6x in August, is now only generating half the returns of the benchmark on a YTD basis. The Q3 event appears to have spooked investors and we dive in to cover some of the key themes. We close with some thoughts on how investors should approach TMDX now.
